NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) posted its quarterly earnings data on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

5 equities research analysts have issued twelve-month price targets for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' stock price to reach $26.75 in the next year. This suggests a possible upside of 517.8% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Headlines about ACER stock have been trending somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acer Therapeutics earned a news impact score of 1.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Acer Therapeutics.

Acer Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 442,900 shares, a drop of 8.8% from the December 15th total of 485,900 shares. Based on an average daily trading volume, of 49,800 shares, the short-interest ratio is presently 8.9 days. Currently, 9.1% of the company's stock are sold short. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include Obseva (OBSV), PhaseBio Pharmaceuticals (PHAS), Galectin Therapeutics (GALT), Akorn (AKRX), Spero Therapeutics (SPRO), TAIWAN LIPOSOME/S (TLC), Corvus Pharmaceuticals (CRVS), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), CannTrust (CTST), Adamas Pharmaceuticals (ADMS), Menlo Therapeutics (MNLO), Selecta Biosciences (SELB), ContraFect (CFRX) and Sierra Oncology (SRRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Arena Pharmaceuticals (ARNA), DryShips (DRYS), Madrigal Pharmaceuticals (MDGL), NVIDIA (NVDA), Actinium Pharmaceuticals (ATNM) and Advanced Micro Devices (AMD).

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $4.33.

Acer Therapeutics has a market capitalization of $43.71 million. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]